Finanzen von Inhibrx Biosciences Inc (INBX)INBXInhibrx Biosciences Inc

Evaluating the bottom line, Inhibrx Biosciences Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -1773.60%, provide a clear picture of how effectively INBX converts its operational activities into shareholder value.

In the context of the broader market, INBX competes directly with industry leaders such as SEPN and NTLA. With a market capitalization of $1.84B, it holds a significant position in the sector. When comparing efficiency, INBX's gross margin of N/A stands against SEPN's 100.00% and NTLA's 100.00%. Such benchmarking helps identify whether Inhibrx Biosciences Inc is trading at a premium or discount relative to its financial performance.

Inhibrx has reported zero revenue in several quarters, with a recent quarterly revenue of $1.3 million in Q2 2025. The company has a gross margin of 100% for certain quarters, but net income remains negative, indicating financial instability.